How to Choose the Right Supplements: A 5-Step Guide to Your Wellness Ritual

The Australian supplement market generates approximately A$2.4 billion in annual retail sales across more than 30,000 listed therapeutic goods — a number that reflects both the scale of public investment in nutritional health and the extraordinary diversity of product quality, clinical validity, and value that this category encompasses. At one end of the spectrum are pharmaceutical-grade, individually TGA AUST L-listed formulations providing individually disclosed ingredient forms and milligram quantities traceable to published peer-reviewed clinical evidence at doses that match the trial protocols. At the other end are products whose active ingredient quantities are concealed behind proprietary blend totals, whose ingredient forms are the least expensive rather than the most bioavailable, and whose front-panel claims reference studies conducted at doses three to ten times higher than the product actually provides. Both extremes carry TGA AUST L numbers. Both appear on the same pharmacy shelf. Both claim the same health outcomes in comparable language. The regulatory framework that governs their presence in the Australian market was designed to ensure safety and manufacturing quality — not to guarantee clinical efficacy, and not to ensure that the dose or form present is the one the health claim implicitly relies upon.

Learning how to choose the right supplements in Australia requires a five-step clinical framework that goes substantially deeper than reading the front panel or trusting that TGA listing alone differentiates clinical quality from compliant label-dusting. This guide covers that framework: from defining the health goal and mapping it to the clinical evidence, through dietary gap assessment, label decoding (including the proprietary blend problem, the form hierarchy, and the therapeutic versus RDI dose distinction), TGA regulatory understanding, and the nutrient timing and combination pharmacokinetics that determine whether a protocol's components actually reach the biological targets the evidence requires.

Step 1: Define Your Health Goal and Map It to the Clinical Evidence

The first and most consequential step in how to choose the right supplements is not browsing the supplement aisle or reading product reviews. It is defining the specific health outcome you are targeting with sufficient precision to identify the clinical evidence that supports a nutritional intervention for that outcome — because the clinical evidence is what identifies the ingredient, the form, and the dose that the biology of your goal requires. A goal of "better sleep" is insufficiently precise: it does not distinguish between difficulty with sleep onset (GABA-A receptor potentiation insufficiency, typically a magnesium glycinate or ashwagandha problem), early morning awakening (cortisol excess, also a magnesium or ashwagandha problem), poor sleep architecture with inadequate slow-wave sleep (an entirely different mechanism addressed by different compounds), or sleep disruption from circadian rhythm dysregulation (a D3 and melatonin timing problem). Each of these sleep presentations has a distinct cellular mechanism, a distinct nutritional intervention, and a distinct body of clinical evidence — and selecting the wrong supplement for the wrong mechanism produces the frustrating experience of expensive products that "don't work."

The practical first-step framework is to define your goal in mechanistic terms rather than symptomatic terms. Not "more energy" but "reduce afternoon cognitive fatigue from mitochondrial ATP insufficiency" (NAD+, CoQ10, ALA) versus "increase morning energy from poor sleep consolidation" (magnesium, sleep architecture support) versus "improve exercise energy capacity and recovery" (CoQ10, omega-3, antioxidant network). Not "immune support" but "reduce frequency and duration of upper respiratory infections" (zinc glycinate, selenomethionine, Vitamin C, Vitamin D) versus "reduce autoimmune inflammatory tone" (curcumin, omega-3 EPA, Vitamin D) versus "accelerate wound healing" (zinc, Vitamin C, Vitamin A). The more precisely you can articulate the mechanism of the outcome you are seeking, the more precisely you can identify the clinical evidence that maps to a specific ingredient, form, and dose. The Zenutri health quiz performs this goal-to-mechanism mapping for you based on your specific symptom and lifestyle profile — identifying the biological mechanism most likely to explain your specific combination of symptoms and directing you to the formulations designed to address it.

The Goal-to-Evidence Mapping for Zenutri's Core Health Priorities

The Zenutri formulation range maps across the most clinically supported supplement goals for Australian adults as follows. Cognitive performance and memory encoding: NAD+ restoration through nicotinamide riboside for SIRT1-CREB-BDNF neuroprotection (Brenner 2018, Nature Communications) and NF-κB neuroinflammation modulation through curcumin with BioPerine for BDNF upregulation (Shoba 1998, Planta Medica) — addressed through the Zenutri NeuroFocus bundle. Bone mineralisation and cardiovascular calcium regulation: D3 1,000 IU and MK-7 180mcg in the co-formulation validated by the Knapen 2013 MK-7 RCT and the Geleijnse 2004 cardiac mortality cohort — through Osteo+Core (AUST L 520792). Sleep quality and anxiety management: magnesium amino acid chelate for GABA-A potentiation and HPA axis cortisol regulation (Abbasi 2012, JRMS) — through MagLipo Core (AUST L 520793). This goal-to-evidence mapping ensures every product recommendation traces to a specific mechanistic rationale and a specific clinical trial outcome rather than a general wellness claim.

Step 2: Assess Your Dietary Foundation and Identify Your Specific Gaps

The gap between dietary intake and nutritional adequacy in the Australian context is not primarily a question of how "healthy" your diet is — it is a question of whether the specific nutrient, in the bioavailable form required for the biological function you are targeting, is present in your diet at the dose the relevant cellular enzyme system requires. As established in the signs of vitamin deficiency article in this series, several mechanisms produce genuine nutritional gaps in adults eating thoughtfully: phytate inhibition of zinc and iron absorption from whole-grain and legume-based "healthy" dietary patterns, age-related gastric atrophy impairing B12 and mineral absorption independently of dietary intake, statin medication suppressing CoQ10 synthesis via the shared mevalonate pathway, and the UV-safety paradox producing Vitamin D insufficiency despite Australian sun exposure.

The dietary gap assessment framework for choosing supplements requires answering four questions honestly. First: does your dietary pattern create predictable absorption limitations? Plant-predominant, high-phytate, or low-animal-product diets create specific and predictable gaps in zinc, B12, and iron that supplement formulations should address with absorption-appropriate forms (zinc glycinate for phytate environments, methylcobalamin for B12). Second: does your age or health history create absorption mechanism impairment? Adults over 50 should assume some degree of decline in intrinsic factor and gastric acid, affecting B12 and mineral absorption. Third: Do your medications create specific nutrient depletions? The statin-CoQ10, metformin-B12, and PPI-magnesium depletion mechanisms are among the most clinically significant drug-nutrient interactions in the Australian population. Fourth: does your specific Australian lifestyle context create environmental oxidative or deficiency pressures? High sun exposure requiring antioxidant UV protection, high-stress professional environments creating magnesium depletion, and predominantly indoor work limiting Vitamin D synthesis are the most prevalent Australian lifestyle gap generators. The answers to these four questions identify the nutritional gaps most likely to be present in your specific biological context — the starting point for selecting formulations that address the actual gaps rather than the statistically average gaps of a hypothetical generic adult.

The Three Dietary Patterns Most Likely to Create Specific Supplement Needs in Australia

Three dietary patterns are particularly common among Australian adults seeking supplement guidance and each creates a predictable nutritional gap profile that informs formulation selection. The plant-predominant or vegetarian pattern — associated with phytate-mediated zinc and iron absorption inhibition, B12 insufficiency from animal product restriction, and DHA inadequacy from ALA conversion inefficiency — requires the zinc glycinate and selenomethionine combination of Immunaxis (AUST L 521494), the methylcobalamin-containing activated B-complex of CurcuNova (AUST L 520796), and an algae-derived DHA source for omega-3 structural adequacy. The high-stress, high-processed-food pattern common in Australian professional adults — associated with cortisol-driven magnesium renal wasting, B-vitamin depletion from adrenal demand and metabolic B-vitamin consumption, and oxidative stress from processed food-derived advanced glycation end products — prioritises the magnesium amino acid chelate and ALA mitochondrial redox support of MagLipo Core (AUST L 520793) and the NF-κB and Nrf2 antioxidant signalling of CurcuNova. The midlife adult pattern over 45, characterised by statin therapy, moderate dietary variety, and declining B12 absorption efficiency, prioritises CoQ10 at 150mg in UbiQ Forte (AUST L 520795), the D3 and MK-7 combination of Osteo+Core (AUST L 520792), and the activated B12 of CurcuNova's B-complex. These pattern-specific gap profiles are the clinical rationale for the Zenutri bundle architecture — not arbitrary ingredient combinations, but mechanistically justified responses to the specific gap profiles of specific Australian adult demographics.

Step 3: Decode the Label — Form, Dose, and the Proprietary Blend Problem

The supplement label is the primary source of information for evaluating clinical quality — and it is the site of the most systematic obfuscation in the supplement industry. Three specific label-reading skills distinguish a supplement that will produce clinical outcomes from one that will not.

Skill One: Identify the Ingredient Form and Apply the Bioavailability Hierarchy

For every mineral or vitamin on a supplement label, the specific chemical form — the salt, chelate, ester, or coenzyme that follows the nutrient name — is more clinically important than the quantity stated. The form determines what proportion of the stated milligram quantity actually reaches systemic circulation and the target cellular compartment. The bioavailability hierarchy for the most commonly supplemented nutrients, based on the pharmacokinetic evidence reviewed throughout this series, is as follows. Magnesium: glycinate or amino acid chelate (superior, absorbed via peptide transport) >> citrate (moderate, osmotic effect limits dose) >> oxide (approximately 4 percent absorption per Gröber 2015). Zinc: glycinate (superior, amino acid chelate transport) >> citrate >> gluconate >> oxide or sulphate (lower bioavailability, gastrointestinal irritation common). B12: methylcobalamin (active coenzyme, immediately bioavailable) = adenosylcobalamin (active mitochondrial coenzyme) >> hydroxocobalamin (intermediate) >> cyanocobalamin (requires hepatic conversion, sub-optimal for adults with gastric atrophy). Vitamin E: natural mixed tocopherols (d-alpha + d-gamma + d-delta; provides the reactive nitrogen species quenching of gamma-tocopherol absent from synthetic form per Jiang 2001) >> natural d-alpha tocopherol >> synthetic dl-alpha-tocopherol. Vitamin K2: MK-7 (72-hour plasma half-life, once-daily dosing sufficient, bone and cardiovascular matrix Gla protein activation confirmed by Knapen 2013) >> MK-4 (short half-life, requires multiple daily doses at much higher amounts for equivalent outcome). CoQ10: ubiquinol (reduced form, direct antioxidant) = ubidecarenone (oxidised form — converted to ubiquinol post-absorption) at standard supplementation doses. When reading any supplement label, confirm the form immediately after the ingredient name — if it is simply listed as "Zinc" or "Magnesium" without a form specified, the manufacturer is concealing the relevant quality information.

Skill Two: Verify the Therapeutic Dose Against the Clinical Evidence

Once you have confirmed the ingredient form, verify that the stated milligram quantity matches the dose range used in the clinical studies that established efficacy for your specific health goal. The gap between the dose that "appears on the label" and the dose that "matches the clinical evidence" is where most generic supplements fail. MK-7 K2: the Knapen 2013 bone mineral density RCT used 180mcg daily — this is the specific dose in Osteo+Core (AUST L 520792). Generic products commonly provide 45 mcg to 90 mcg, which is between one-quarter and one-half of the evidence-validated dose. CoQ10: the Fotino 2013 meta-analysis identified 150mg as the minimum dose for meaningful cardiovascular and metabolic outcomes — generic products in the 30mg to 50mg range provide one-fifth to one-third of this threshold. NR: the Brenner 2018 trial used 100mg to 300mg and confirmed significant NAD+ elevation — Reversa NR (AUST L 520794) provides 150mg. The label-reading discipline is to write down the clinical evidence dose for your target outcome before purchasing and compare it to the label's stated quantity in the verified bioavailable form. If the product provides a sub-threshold dose, it will produce a sub-threshold outcome regardless of the front-panel health-claim language.

Skill Three: Detect and Reject Proprietary Blends

A proprietary blend on an Australian supplement label is a group of ingredients listed under a collective branded name with a single total weight but no individual component quantities. The blend format is used when manufacturers wish to present an impressive ingredient list without disclosing the actual per-ingredient quantities — which in the vast majority of proprietary blend products would reveal that each active compound is present at a fraction of its therapeutic dose, with the majority of the blend's weight accounted for by the cheapest or most voluminous ingredient. Identifying a proprietary blend on a label is straightforward: look for a section that names a blend (e.g., "Nootropic Matrix," "Antioxidant Complex," "Energy Blend") followed by a total weight in milligrams and a list of ingredients inside the blend without individual weights beside each one. The presence of any proprietary blend in a supplement you are considering is an immediate red flag — not because it is necessarily harmful, but because it makes clinical quality assessment impossible. If a manufacturer is unwilling to disclose that their "Cognitive Support Blend 350mg" contains, for example, 180mg of NR rather than 20mg, there is a reason for that non-disclosure. All Zenutri formulations provide individually disclosed ingredient forms and milligram quantities for every active component — no proprietary blends, no concealed quantities, no gap between the label and the cellular delivery it represents.

Step 4: Understand TGA Regulation and the Quality Markers That Matter

Australia's Therapeutic Goods Administration provides the most stringent pre-market regulatory framework for supplements of any major market globally — and understanding what the AUST L number does and does not guarantee is essential for using TGA listing as an effective quality filter rather than treating it as a simple "safe to use" badge that does not distinguish clinical quality.

The AUST L (listed medicine) pathway confirms four things: the product is manufactured in a TGA-licensed facility operating under current Good Manufacturing Practice (cGMP) standards, with batch-by-batch identity testing, potency verification, contamination screening (heavy metals, microbiological load), and stability data; each ingredient is on the TGA's permitted list for listed medicines at the stated dose; the label accurately represents the contents as declared to the TGA; and the therapeutic claims on the label do not exceed the indications permitted for the listed medicine category (generally maintenance of health and wellbeing rather than treatment of disease). The AUST L number does not confirm that the dose is clinically relevant, that the form is the most bioavailable, or that a clinical outcome at the stated dose has been demonstrated in peer-reviewed human trials. These quality dimensions require the label-reading skills described in Step 3 — the TGA framework guarantees manufacturing integrity and label accuracy, not clinical efficacy at the stated dose.

Beyond TGA: The Four Additional Quality Markers That Define Clinical Grade

Four quality markers extend the TGA AUST L baseline to the clinical grade standard that distinguishes formulations likely to produce outcomes from those unlikely to: individually disclosed ingredient forms and milligram quantities (no proprietary blends), ingredient forms selected from the bioavailability hierarchy's highest tier rather than the manufacturing cost hierarchy's lowest, doses that match or approach the clinical trial ranges for the stated health outcomes, and batch-specific third-party testing certificates available on request confirming the actual measured potency and contaminant status of each production batch. These four markers — combined with the AUST L manufacturing quality confirmation — constitute the complete quality framework for choosing the right supplements in Australia. All seven Zenutri TGA AUST L-listed formulations meet all four additional markers: individually disclosed forms and quantities, bioavailability-optimised ingredient selection (zinc glycinate, selenium as selenomethionine, MK-7, natural mixed tocopherols, magnesium amino acid chelate, NR, methylcobalamin), doses traceable to clinical evidence, and Australian cGMP manufacture with the quality documentation infrastructure that the TGA ARTG registration system requires manufacturers to maintain.

Step 5: Optimise Timing, Combinations, and Your Personalised Daily Protocol

The final step in the supplement selection framework addresses a dimension that most consumer guidance ignores entirely but that meaningfully affects how much of each formulation's stated dose actually reaches the biological target: chronopharmacology and nutrient combination timing. Chronopharmacology — the study of how the time of dosing relative to biological and circadian rhythms affects pharmacokinetic and pharmacodynamic outcomes — applies to nutritional supplements through the same mechanisms it applies to pharmaceutical drugs: the biological context of nutrient absorption, distribution, and metabolism changes predictably across the 24-hour cycle, and aligning dosing with the periods of highest absorptive efficiency and highest biological demand produces meaningfully superior outcomes compared to arbitrary timing.

Chronopharmacological Timing for the Zenutri Range

The timing principles for the most clinically important supplement classes reflect three converging rationales: absorption optimisation (fat-soluble actives require dietary fat), circadian alignment (certain enzyme activities peak at specific times), and pharmacodynamic matching (certain supplements are most useful when their mechanism is most relevant). Morning with a fat-containing breakfast is the optimal timing for fat-soluble actives (D3, K2, CoQ10, curcumin, resveratrol, natural mixed tocopherols, ALA) — the fat-triggered bile salt secretion and lipid micellar formation that maximise their intestinal absorption is best provided by the main fat-containing meal of the day. B-vitamins, which support daytime energy metabolism, neurotransmitter synthesis, and the methylation cycle's waking-hour demands, are best taken in the morning to align with the peak of metabolic activity. The activated B-complex in CurcuNova (AUST L 520796) taken with morning breakfast satisfies both the fat co-administration requirement for curcumin and the circadian alignment requirement for B-vitamin-dependent methylation cycle activity simultaneously.

Evening dosing is specifically indicated for magnesium, as discussed in the magnesium glycinate article: the GABA-A receptor potentiation that improves sleep onset and the HPA axis cortisol regulation that supports the diurnal cortisol decline required for sleep architecture maintenance are both most pharmacodynamically relevant in the hours before sleep. Ashwagandha, whose withanolide-mediated HPA axis modulation and triethylene glycol-mediated sleep induction operate through mechanisms with slower onset kinetics (30 to 60 minutes), similarly benefits from dosing 1 to 2 hours before intended sleep. These two compounds — addressing the stress-cortisol-sleep axis from complementary angles — can be taken together at the same evening time point, with a light snack containing fat for the withanolide absorption that ashwagandha's fat-soluble constituents require.

Nutrient Competition Interactions and Timing Separation

Three specific nutrient-competition interactions are clinically relevant enough to warrant timing considerations in Australian supplement protocols. Calcium and magnesium compete for intestinal absorption through shared DMT1 divalent metal transporter pathways at high simultaneous doses — separating calcium-rich dairy consumption or calcium-containing supplements from magnesium supplementation by 1 to 2 hours maximises absorption of both, particularly relevant for individuals combining Osteo+Core's D3 (which enhances calcium absorption) with MagLipo Core's magnesium amino acid chelate. Zinc at high supplemental doses (above 50mg daily) competitively inhibits copper absorption through ZIP transporter competition — at the 20mg zinc glycinate dose in Immunaxis (AUST L 521494), this is not clinically significant, but individuals adding external zinc sources should remain within the NHMRC safe upper intake of 40mg daily from supplements to avoid copper displacement. Iron and all mineral co-supplements compete for intestinal transport — iron supplements, where clinically indicated following GP blood test confirmation of deficiency, are most effectively taken separately from other mineral-containing formulations, ideally with Vitamin C (to enhance non-haem iron absorption through Fe³⁺ to Fe²⁺ reduction) and away from the main calcium, magnesium, and zinc supplement timing. For individuals using the complete Zenutri range across multiple formulations, the Zenutri health quiz calculates cumulative nutrient intakes across all recommended products and identifies any combination-specific timing adjustments warranted by the combined profile.

Building Your Personalised Daily Protocol

The practical output of the five-step framework is a specific daily protocol with defined timing and food co-administration requirements for each formulation. For most Australian adults working through the Zenutri system, the morning fat-containing breakfast protocol covers the majority of active components (all fat-soluble actives in CurcuNova, C E B Optima, Osteo+Core, UbiQ Forte, MagLipo Core, and Reversa NR). If additional magnesium for sleep support is a priority, a small evening dose from MagLipo Core can be split from the morning dose — the total daily magnesium from all Zenutri formulations remains within the NHMRC 2017 safe supplemental upper intake of 350mg daily when used as directed. The 90-day assessment timeline — consistent across this series — applies to the complete personalised protocol: track your three primary target markers, reassess against your initial health goals, and adjust formulation selection based on the outcomes your specific biology demonstrates over that period. Longstanding protocols should be periodically reassessed as life stage, dietary pattern, and health context evolve — which is why the Zenutri health quiz is designed for periodic re-completion rather than as a single-use assessment.

The Supplement That Works Is the One That Reaches the Target

The five-step framework for how to choose the right supplements in Australia converges on a single principle that every step in the framework exists to protect: the supplement that produces the clinical outcome you are seeking is the one that delivers the correct compound in the correct molecular form at the correct dose to the correct cellular target with a consistency that allows the biological mechanism to operate at the level the clinical evidence describes. Every quality compromise in the supply chain — inferior ingredient form, sub-threshold dose, proprietary blend concealment, poor timing, competitive absorption interference — reduces the probability that the product you have invested in is actually engaging the biology it claims to address. The TGA AUST L framework guarantees that the product exists as described and was manufactured to pharmaceutical standards. The five-step evaluation framework ensures that what exists as described is, in fact, what the clinical evidence requires for your specific biological context and health goal.

Every Zenutri formulation was designed to meet all five criteria simultaneously — TGA AUST L manufacture, disclosed ingredient forms and quantities, bioavailability-hierarchy forms, clinical-evidence-matched doses, and the bundle architecture that aligns the right combination of formulations to the right gap profile for the right Australian adult demographic. Not sure which combination maps to your specific goals and gaps? Take the free five-minute Zenutri health quiz to receive a personalised protocol recommendation that performs Steps 1 through 5 of this framework for your specific profile. Or explore the full Zenutri bundle collection to browse by health goal.

Frequently Asked Questions

What is the difference between TGA-listed (AUST L) and TGA-registered (AUST R) supplements in Australia?

An AUST L (listed medicine) number confirms that a supplement was manufactured in a TGA-licensed cGMP facility, that its ingredients are on the TGA's permitted list for listed medicines at the stated doses, and that the label accurately represents the contents declared to the TGA. The AUST L pathway covers most vitamins, minerals, and herbal supplements. An AUST R (registered medicine) number additionally requires pre-market efficacy assessment — the TGA reviews clinical evidence before granting registration, and the therapeutic claims are specifically evidence-assessed rather than limited to the general indications permitted for listed medicines. The practical consumer implication: an AUST L number is a meaningful quality guarantee that what the label states is present and was made to pharmaceutical standards, which is substantially more protection than the food-category self-affirmation framework that governs imported supplements from most international markets. All seven Zenutri formulations carry individual AUST L numbers verifiable on the TGA ARTG database.

How do I know if a supplement is providing a therapeutic dose?

A therapeutic dose is the amount of an active ingredient in a bioavailable form that the published clinical evidence identifies as required to produce a specific biological outcome. To verify therapeutic dosing, you need three pieces of information: the clinical study that established efficacy for your target outcome (and the dose used in that study), the ingredient form in that study, and the milligram quantity per serving on the supplement label you are evaluating. Compare the label quantity to the study dose in the verified form: the Knapen 2013 MK-7 bone RCT used 180mcg — if your Vitamin K2 supplement provides 45mcg as MK-4 (different form, shorter half-life), it is providing neither the correct form nor dose. Osteo+Core (AUST L 520792) provides 180mcg MK-7, matching the evidence-validated dose in the evidence-validated form. The same analysis applies to every active ingredient across the Zenutri range, with the clinical references provided throughout this blog series enabling direct dose verification for each compound.

What are proprietary blends and why should I avoid them?

Proprietary blends are multi-ingredient groupings on a supplement label that disclose a single combined total weight without revealing the individual milligram quantities of each component ingredient. A "Cognitive Support Blend 500mg" listing eight ingredients provides no information about whether any of those ingredients is present at a dose the clinical evidence associates with a meaningful effect — the total 500mg could be 450mg of the cheapest filler ingredient and 6.25mg of each of the seven active compounds, all below any clinical threshold, with each ingredient name still appearing on the front panel. Proprietary blend labelling is permitted under TGA-listed medicine regulations, but is incompatible with clinical quality assessment. All Zenutri formulations individually disclose every ingredient, its form, and milligram quantity — there are no proprietary blends in the Zenutri range, and any competitor product containing one cannot be meaningfully evaluated for clinical adequacy, regardless of the apparent comprehensiveness of its ingredient list.

Should I take supplements with food?

The answer depends on the ingredient class. Fat-soluble nutrients — Vitamin D3, K2 (MK-7), CoQ10, curcumin, resveratrol, mixed tocopherols, ALA, and astaxanthin — all require dietary fat to trigger the bile salt secretion and lipid micellar formation that facilitate their intestinal absorption. Taking these on an empty stomach substantially reduces bioavailability regardless of dose. In practice: any supplement containing curcumin, CoQ10, D3, K2, or fat-soluble vitamins should be taken with a main meal containing 10 to 15 grams of healthy fat — a breakfast with eggs, avocado, olive oil, or oily fish satisfies this requirement. Water-soluble vitamins (B-complex, Vitamin C) absorb without dietary fat but benefit from fed-state administration for tolerability. Magnesium glycinate can be taken with or without food due to its amino acid transport absorption pathway, but evening with a small snack optimises the sleep-support timing.

Can I take multiple supplements at the same time?

Most quality supplement combinations can be taken simultaneously. The specific nutrient competition interactions that warrant timing management are: calcium at high doses (above 500mg) with magnesium — a 1 to 2-hour separation improves absorption of both; zinc above 50mg daily — copper competitive inhibition threshold (not an issue at Immunaxis's 20mg zinc glycinate dose); iron with calcium, magnesium, or zinc — iron supplements are best taken separately from mineral-containing formulations. Within the Zenutri range, all formulations are designed for simultaneous morning co-administration with a fat-containing breakfast, with the exception of magnesium used specifically for sleep support (evening timing) and any GP-prescribed iron supplementation (separate timing as above). The Zenutri health quiz accounts for all combination nutrient interactions when generating personalised protocol recommendations.

Is a more expensive supplement always of better quality?

Higher cost does not automatically indicate higher quality — but genuinely high clinical quality does require higher cost, because superior ingredient forms (zinc glycinate versus zinc oxide, MK-7 versus MK-4, NR versus niacin) are substantially more expensive to source and manufacture. The practical framework: compare price against the four clinical quality markers described in Step 4 — individual ingredient form disclosure, bioavailability-hierarchy form selection, dose alignment with clinical evidence, and TGA AUST L cGMP manufacture. A product that meets all four markers at a higher price is providing genuine value per unit of biological outcome delivered. A product at a low price that provides magnesium oxide (4% absorption), synthetic dl-alpha-tocopherol (pro-oxidant risk, missing gamma-tocopherol), and MK-4 K2 at 45mcg behind proprietary blend labelling is not a budget alternative to higher-quality formulations — it is a product producing no meaningful clinical outcome at any price point, which is the most expensive possible supplement per unit of health benefit achieved.